Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLIRST III: aBMC for Critical Limb Ischemia
NCT02538978Phase 3Unknown
- Sponsor
- ThermoGenesis
- Start
- Jan 2017
- Primary completion
- Dec 2018
- Modality
- Stem Cell Therapies
01
Overview
A Phase 3 trial of autologous bone marrow cell concentrate in critical limb ischemia (CLI), sponsored by ThermoGenesis. Status: unknown.
02
Drugs
autologous bone marrow cell concentrate
03
Conditions
critical limb ischemia (CLI)
Beyond the preview
Go deeper on NCT02538978.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02538978.